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The anaphase-promoting complex (APC) regulates cell divi-
sion in eukaryotes by targeting specific proteins for destruction.
APC substrates generally contain one or more short degron
sequences that help mediate their recognition and poly-ubiq-
uitination by the APC. The most common and well character-
ized degrons are the destruction box (D box) and the KEN box.
The budding yeast Acm1 protein, an inhibitor of Cdh1-acti-
vated APC (APCCdh1) also contains several conserved D and
KEN boxes, and here we report that two of these located in the
central region of Acm1 constitute a pseudosubstrate sequence
required for APCCdh1 inhibition. Acm1 interacted with and
inhibited substrate binding to the WD40 repeat domain of
Cdh1. Combined mutation of the central D and KEN boxes
strongly reduced both binding to the Cdh1 WD40 domain and
APCCdh1 inhibition. Despite this, the double mutant, but not
wild-type Acm1, was poly-ubiquitinated by APCCdh1 in vitro.
Thus, unlike substrates in which D and KEN boxes promote
ubiquitination, these same elements in the central region of
Acm1 prevent ubiquitination. We propose that this unique
property of the Acm1 degron sequences results from an unusu-
ally high affinity interaction with the substrate receptor site on
theWD40 domain of Cdh1 thatmay serve both to promoteAPC
inhibition and protect Acm1 from destruction.
The anaphase-promoting complex (APC),4 is a highly con-
served multisubunit ubiquitin ligase and an important regula-
tor of eukaryotic cell division (1). It targets key cell cycle pro-
teins for proteolysis via the ubiquitin pathway (2), including
securin, an inhibitor of chromosome segregation, and the S and
M phase cyclin subunits of cyclin-dependent kinase (CDK).
Securin proteolysis triggers the initiation of anaphase once all sis-
ter chromatidshavebeenproperlybi-orientedon themitotic spin-
dle during metaphase (3–5). Cyclin proteolysis leads to inactiva-
tionofCDK,which isnecessary forcells toexit frommitosis (6–8).
In addition, APC controls the destruction of numerous other pro-
teins such as Aurora A kinase, Polo-like kinases, the APC co-acti-
vatorCdc20, the Skp2F-boxprotein, various spindle components,
and replication factors such as Cdc6, Dbf4, and geminin (1). Sev-
eral of these substrateswere recently reported to beoverexpressed
in a wide range of malignant cancers (9), highlighting the critical
role APC plays inmaintaining genomic stability and proper regu-
lation of the cell division cycle.
Although many substrates of APC have been identified, the
mechanism by which they are specifically recognized is still
poorly understood. Substrate recognition was originally pro-
posed to be mediated by the Cdc20 and Cdh1 proteins, two
related WD40 repeat domain proteins that are essential for
APC activity at different times during the cell cycle (10, 11). The
identification of direct interactions between these co-activators
and several substrates (12–16) led to a model for APC activa-
tion in which Cdc20 and Cdh1 acted as substrate-recruiting
factors,much like the F-box proteins of the SCF ubiquitin ligase
(17). However, more recent work suggests that APC and co-
activator together contribute to substrate recognition (18–23),
and evidence emerged that APC itself can interact directly with
substrates (24, 25). Unfortunately, the exact mechanism by
which Cdc20 and Cdh1 activate APC remains unclear.
Because substrate selectivity byAPC in vivo is highly specific,
one might expect substrates to share common sequence motifs
required for their recognition. To a certain extent this is true.
The destruction box (D box) was originally identified as a con-
served 9-amino acid motif in sea urchin cyclin B (26). Muta-
tions in the D box (consensus RXXLXXXXN) in cyclin B pre-
vented its ubiquitination and proteolysis. Functional RXXL D
boxes are found in the majority of APC substrates, but not all.
Additional short amino acid sequences have subsequently been
identified that can direct APC-dependent ubiquitination and
proteolysis either in the absence of, or in conjunction with, D
boxes. Themost common and well characterized of these addi-
tional degrons is the KEN box, originally identified in human
Cdc20 (27), but now found inmany APC substrates. Additional
degrons include the A box found in Xenopus Aurora A kinase
(28, 29), the CRY box found inmammalian Cdc20 (30), a GxEN
sequence in the Xenopus chromokinesin XKid (31), and an
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LXEXXXNsequence in budding yeast Spo13 (32). TheKENbox
was thought to be a specific signal for recognition by Cdh1 (27).
This theory has been supported by several studies (33–35), but
exceptions have also been found (12, 36, 37). Moreover, the
existence of the other, apparently unrelated, degrons has fur-
ther clouded the understanding of substrate recognition by
APC. Also, many proteins that are clearly not APC substrates
contain sequences that match the D box, KEN box, and other
APC degrons. Thus, sequence context surrounding the
degrons, and possibly other factors, are clearly important con-
tributors to substrate recognition as well.
A recently identifiedmechanism for regulation of APC activ-
ity is pseudosubstrate inhibition. Pseudosubstrate inhibition is
best characterized in kinases where intramolecular amino acid
motifs mimicking a natural substrate sit in the kinase active site
to suppress activity in the absence of an activating signal (38).
The vertebrate Emi1 protein was recently proposed to be a
pseudosubstrate inhibitor of the APC (39). Emi1 competitively
inhibits substrate binding to theAPC and co-activators (39, 40).
This activity is dependent on a D box in Emi1 suggesting that
Emi1 interacts with APC similar to a true substrate. But why is
it not ubiquitinated like a substrate and targeted for proteoly-
sis? Miller et al. (39) found that the zinc binding domain of
Emi1 was essential for APC inhibition and removal of this
region allowed Emi1 to be ubiquitinated and destroyed in a D
box-dependent manner. Thus, the Emi1 D box promotes high
affinity binding to the substrate recognition site on the coacti-
vator-APC complex while the zinc binding region blocks the
catalytic activity of APC. The yeast Mad3 protein, an essential
component of the spindle checkpoint that inhibits APCCdc20
activity, was also proposed to act by a pseudosubstrate mecha-
nism (36). This conclusion was based on the observation that
mutations in two conserved KEN boxes and a D box in Mad3
compromise its interaction with Cdc20, its ability to block sub-
strate binding toCdc20, and its ability to function in the spindle
checkpoint. Another recent report obtained similar results but
also provided evidence that Mad3 is a substrate of APCCdh1
(37), raising the intriguing possibility that it inhibits one formof
APC (APCCdc20) and is a substrate of the other (APCCdh1).
Pseudosubstrate inhibitors will likely be useful models for fur-
ther defining the determinants of APC substrate recognition.
Recently, the budding yeast Acm1 protein was identified as a
stable binding partner of Cdh1 and an inhibitor of APCCdh1
activity (41, 42) that contributes to spindle pole body separation
(43). Acm1 contains conserved D box and KEN box sequences,
suggesting that it also could be a pseudosubstrate inhibitor sim-
ilar to Emi1 andMad3.We have addressed that hypothesis here
by studying the effects of D and KEN box mutations in Acm1.
We conclude that Acm1 is indeed a pseudosubstrate inhibitor
of APCCdh1. Interestingly, we observed a unique property of aD
and KEN box pair in the central region of Acm1 required for
high affinity Cdh1 binding andAPCCdh1 inhibition. Contrary to
their typical functions in APC substrates, these sequences pre-
vent APCCdh1-catalyzed ubiquitination of Acm1. This could be
important to promote the inhibitory function of Acm1 by pro-
tecting it from destruction.We discuss the implications for our
understanding of substrate recognition and mechanisms of
APC activation.
EXPERIMENTAL PROCEDURES
Strains, Plasmids, and Yeast Methods—Standard media and
growth conditions were used for all yeast experiments.
All yeast strains and plasmids used in this study are listed in
Table 1. Strain YKA294 was constructed by PCR-mediated
replacement of the ACM1 coding sequence in YKA291 (42)
with theKanMX4cassette using standard procedures. Plasmids
pHLP127 and pHLP128 expressing 3FLAG-tagged Cdh1 trun-
cations 1–249 and 241–566, respectively, were constructed by
amplifying the desired sequence by PCR and replacing the
intactCDH1 sequence frompHLP130 (42) usingNotI andXhoI
restriction sites. pHLP273 was constructed by subcloning the
XbaI-XhoI fragment from pHLP128 into p413ADH. Mutation
of Acm1 degron residues (Arg and Leu of the D boxes and Lys,
Glu, and Asn of the KEN box) to alanine were generated by
site-directed mutagenesis using the QuikChange kit (Strat-
agene) and either pHLP117 or pHLP109 (42) as template. All
mutations and all plasmids constructed using PCR were con-
firmed by DNA sequencing. Other plasmids and yeast strains
have been described previously (see Table 1 for references).
Plasmids for in vitro transcription and translation to generate
substrates for the ubiquitination assay were constructed by
amplifying genes by PCR from yeast genomic DNA or available
plasmid constructs and inserting the products into the NcoI
and XhoI sites in pET28a. For HSL1 and FIN1, we used previ-
ously described gene fragments encoding the truncated amino
acid sequences 667–872 and 1–152, respectively, which are
sufficient for recognition by APCCdh1 (12, 44). ACM1 trunca-
tions were based on secondary structure predictions. Clb2 was
synthesized from pRSET-CLB2 (18).
TABLE 1
Yeast strains and plasmids
Strain Background and relevant genotype Source
YKA150 W303MATa bar1::URA3 (45)
YKA155 W303MATa bar1::URA3 CDC27-3FLAG:KanMX4 (45)
YKA226 BY4741MATa 3HA-ACM1 (42)
YKA247 W303MATa bar1::URA3 acm1::KanMX4 (42)
YKA254 W303MATa acm1::KanMX4 (49)
YKA257 BY4741MATa bar1::hisG 3HA-HSL1
acm1::KanMX4
(42)
YKA294 BY4741MATa bar1::hisG 3FLAG-CDH1
acm1::KanMX4
This study
Plasmid namea Marker Promoter Expressed protein
pHLP109 LEU2 GAL1 HA-Acm1
pHLP110 LEU2 GAL1 HA-Acm1–5A
pHLP117 LEU2 ACM1 3HA-Acm1
pHLP121 LEU2 GAL1 HA-Acm1-db1
pHLP122 LEU2 GAL1 HA-Acm1-db3
pHLP123 LEU2 GAL1 HA-Acm1-ken
pHLP126 LEU2 GAL1 HA-Acm1-db1/db3/ken
pHLP127 LEU2 ADH 3FLAG-Cdh1-(1–249)
pHLP128 LEU2 ADH 3FLAG-Cdh1-(241–566)
pHLP132 LEU2 ACM1 3HA-Acm1-db1
pHLP133 LEU2 ACM1 3HA-Acm1-db3
pHLP134 LEU2 ACM1 3HA-Acm1-ken
pHLP140 LEU2 ACM1 3HA-Acm1-db1/db3
pHLP148 LEU2 ACM1 3HA-Acm1-db1/ken
pHLP149 LEU2 ACM1 3HA-Acm1-db3/ken
pHLP151 LEU2 ACM1 3HA-Acm1-db1/db3/ken
pHLP158 LEU2 ACM1 3HA-Acm1-db2
pHLP159 LEU2 ACM1 3HA-Acm1-db1/db2
pHLP231 TRP1 GAL1 3FLAG-Cdh1
pHLP273 HIS3 ADH 3FLAG-Cdh1-(241–566)
pHLP274 LEU2 GAL1 HA-Acm1-db3/ken
a All plasmids carry a CEN/ARS origin for the low copy number.
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Protein Purification—To isolate APC, Cdc27–3FLAG was
immunoaffinity-purified from YKA155 essentially as described
(45) and stored in small aliquots at 80 °C immediately after
elution from anti-FLAG antibody resin. 3FLAG-Cdh1 was
purified as described (46) except phosphatase inhibitors were
omitted and, following elution from anti-FLAG resin, was dia-
lyzed into storage buffer (25 mMHEPES, pH 7.8, 100 mMNaCl,
50% glycerol) for 6 h. Aliquots were stored at 80 °C, and a
working aliquot was kept at 20 °C, which maintained activity
for at least a couple months. Ubc4-His6 and wild-type and
mutant His6-Acm1 proteins were overexpressed in Escherichia
coli and purified by Ni2-affinity chromatography using 1-ml
HisTrap columns and an ÁKTA fast-protein liquid chromatog-
raphy system (GE Healthcare), dialyzed into storage buffer
overnight, and stored in aliquots at 80 °C. Working aliquots
were kept at20 °C. All protein concentrations were estimated
by densitometric analysis of Coomassie Blue-stained polyacryl-
amide gels using a bovine serum albumin standard curve.
UbiquitinationAssay—L-[35S]Methionine (GEHealthcare or
MP Biomedicals) was used to label APC substrates in TNT
QuickCoupledTranscription/Translation reactions (Promega,
Madison, WI) according to the product instructions. Ubiquiti-
nation reactions were based largely on assays from theMorgan
and Barford groups (47, 48) and contained 200 nM yeast Uba1
(Boston Biochem), 10 M Ubc4-His6, 100 nM 3FLAG-Cdh1,
2 nM APC, 1 mg/ml recombinant human ubiquitin (Boston
Biochem), 20 g/ml ubiquitin aldehyde (Boston Biochem), 25
MMG-132 (Peptides International), and 3–4 l of the appro-
priate TNT-generated 35S-labeled substrate all in 20 mM
HEPES, pH 7.8, 5 mM ATP, 10 mM MgCl2, and 0.5 mM dithio-
threitol. The Uba1, Ubc4-His6, and ubiquitin were preincu-
bated together in the presence of Mg2-ATP first for 10 min at
23 °C to generate ubiquitin-charged E2 prior to addition of the
remaining components. Reactions (20 l of total volume) were
incubated at 23 °C for 30 min and stopped by boiling in SDS
loading buffer. Products were resolved by SDS-PAGE, and
dried gels were subjected to PhosphorImager analysis using a
Molecular Dynamics Typhoon 8600 imaging system and
ImageQuant software.
Co-immunoprecipitation—Co-IP assays were performed
exactly as described (42, 49).Where indicated,NaCl concentra-
tion was adjusted from 100 mM to 400 mM. For immunoblot-
ting, anti-HA 12CA5 (Roche Applied Science) was used at
1:1,000 and anti-FLAG M2 (Sigma) at 1:10,000 dilutions.
Immunoblots were developed with ECL plus reagents (GE
Healthcare).
Protein Stability and Cell Cycle Profiles—Protein stability
was measured by galactose promoter shutoff assays exactly as
described (49). Cell cycle expression profiles were determined
by -factor block and release and immunoblotting as described
(42).
In Vivo APC Inhibition Assay—Inhibition of APCCdh1 was
measured in vivo as described previously (42).
RESULTS
Acm1 Is a General Inhibitor of APCCdh1 Activity Independent
of 14-3-3 Binding and Phosphorylation—Acm1 purified from
yeastwas previously shown to inhibit the ubiquitination ofClb2
by APCCdh1 in vitro (41). We first wanted to know if Acm1 is a
general inhibitor of APCCdh1 or is specific for Clb2, and also to
determine if CDK phosphorylation and 14-3-3 protein binding,
two known regulatory mechanisms controlling Acm1 stability
(41, 42, 49), were important for inhibitory function. This infor-
mation was critical to establishing an appropriate in vitro assay
to study themechanism of APCCdh1 inhibition by Acm1. To do
this, we tested the ability of recombinant His6-Acm1 purified
from E. coli to inhibit APCCdh1-catalyzed ubiquitination of the
well characterized substrates Hsl1667–872 (12), Fin11–152 (44),
and Pds1 (3), in addition to Clb2 (Fig. 1, A and B). Acm1 effec-
tively inhibited ubiquitination of all four substrates and showed
a similar concentration dependence for each.We conclude that
Acm1 is a general inhibitor of APCCdh1 activity.
The results in Fig. 1 using recombinant His6-Acm1 also
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FIGURE 1. Acm1 is a general inhibitor of APCCdh1, independent of CDK
phosphorylation and 14-3-3 protein binding. A, APCCdh1-catalyzed ubiq-
uitination of [35S]methionine-labeled substrates Clb2, Hsl1667– 872, and
Fin11–152 was assayed in the absence or presence of 125 nM recombinant
His6-Acm1 purified from E. coli as described under “Experimental Proce-
dures.” Reaction products (ubiquitin conjugates) indicated by the bracket are
detected based on reduced mobility during SDS-PAGE. B, inhibition of
APCCdh1-catalyzed ubiquitination of Clb2, Hsl1667– 872, and Pds1 was meas-
ured as in A as a function of recombinant His6-Acm1 concentration. NC is a
negative control lacking APC. Reaction products are labeled “Ubiq. Conj.”
C, 10-fold serial dilutions of strain YKA247 expressing the indicated proteins
from the GAL1 promoter on centromeric plasmids were spotted on rich media
plates containing either glucose or galactose as the carbon source and grown
for several days at 30 °C.
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are not required for APC inhibition. To confirm this, we tested
the ability of an Acm1 mutant lacking CDK phosphorylation
sites, Acm1–5A (49), to inhibit APCCdh1 in vivo. Overexpres-
sion of Cdh1 is lethal due to constitutive APC activity that pre-
vents proper cyclin accumulation and mitotic entry (10, 11).
We previously showed that co-overexpression of Acm1 sup-
presses this lethality (42), establishing an assay to monitor
APCCdh1 inhibition in vivo. The Acm1–5A mutant cannot be
phosphorylated byCDKand is defective in 14-3-3 protein bind-
ing (49), yet when overexpressed in cells containing a lethal
Cdh1 level, it fully restores viability like wild-type Acm1 (Fig.
1C). Thus, Acm1 does not require phosphorylation or binding
to the 14-3-3 proteins Bmh1 and Bmh2 to act as an inhibitor of
APCCdh1.
Conserved D Box and KEN Box Sequences in Acm1 Are
Required for High Affinity Binding to the Substrate Receptor Site
on the Cdh1WD40Domain—Alignment of Saccharomyces cer-
evisiaeAcm1with orthologs from other Saccharomyces species
and other budding yeasts of the order Saccharomycetales
revealed conserved sequence motifs common to APC sub-
strates (Fig. 2). These include a D box near the N terminus (D
box 1) and aD box (D box 3) and KEN box in the central region.
An additional D box in the central region (D box 2) is not con-
served. We speculated that the conserved degron-like
sequences might be important for APC inhibition and that
Acm1 might act as a pseudosubstrate inhibitor like Emi1 and
Mad3 (36, 39). To test this, wemadeD boxmutations (RXXL to
AXXA) and KEN box mutations (KEN to AAA) alone and in
various combinations. First, we examined the ability of mutant
proteins expressed with an N-terminal 3HA tag from the
ACM1 promoter to bind endogenous 3FLAG-Cdh1. Mutation
of D box 1 (db1) and D box 2 (db2) had no effect on Cdh1
binding using a co-IP assay (Fig. 3A).Mutation ofD-box 3 (db3)
or the KEN-box (ken) reduced binding to Cdh1 and combining
the twomutations (db3/ken) eliminated binding toCdh1 in this
assay. Therefore, these two motifs are required for the stable
interaction between Acm1 and Cdh1 detected by co-IP.
Previous evidence suggested that Acm1 could inhibit the
interaction of certain substrateswithCdh1 (41, 42). Because the
WD40 domain of Cdh1 is thought to contain a D-box receptor
that contributes to substrate binding (20), and because Acm1
interaction with Cdh1 is dependent on a D box and KEN box,
we tested whether Acm1 specifically interacts with and inhibits
substrate binding to the Cdh1 WD40 domain. First, we inde-
pendently expressed either the N-terminal regulatory or C-ter-
minal WD40 domain of Cdh1 as a 3FLAG fusion and moni-
tored association with endogenous 3HA-Acm1 by co-IP. The
boundary between the domains was chosen based on a stable
naturally occurring proteolytic fragment of Cdh1 that contains
the entire WD40 region (data not shown). Acm1 interacted
very strongly with the Cdh1 WD40 domain but showed no
interaction with the N-terminal domain (Fig. 3B). The 14-3-3
proteins Bmh1 and Bmh2 were also present in theWD40 com-
plex, as expected (not shown).
The APC substrate Hsl1 forms a stable, direct interaction
with Cdh1 that is dependent on a D box and KEN box and
required for its proteolysis (12). We found that 3HA-Hsl1 also
associated stably with the 3FLAG-Cdh1WD40 domain, con-
sistent with the notion that the WD40 domain contains the
substrate degron receptor(s) on Cdh1 (Fig. 3C, lane 2). Overex-
pressed 3HA-Acm1 displaced 3HA-Hsl1 from 3FLAG-
Cdh1WD40 (Fig. 3C, lane 3), demonstrating that Acm1 and
Hsl1 binding to the Cdh1 WD40 domain are mutually exclu-
sive. The most likely explanation is high affinity competitive
binding of Acm1 to the substrate receptor site.
To confirm that the association between Acm1 and
Cdh1WD40 was also dependent on the central degron
sequences we repeated the co-IPs from Fig. 3A using 3FLAG-
Cdh1WD40 instead of full-length 3FLAG-Cdh1. Surprisingly,
all Acm1 mutants associated with Cdh1WD40 to a similar
extent (not shown). This suggested that additional sequences
within Acm1 contribute to stable WD40 binding. The discrep-
ancy is likely explained by the overexpression of 3FLAG-
Cdh1WD40 from the ADH promoter, whereas full-length
3FLAG-Cdh1 used in Fig. 3A was expressed from its natural
genomic locus.We therefore createdmore stringent co-IP con-
ditions by increasing the salt concentration to 400 mM, match-
ing that used in the original identification of the Acm1-Cdh1
FIGURE 2. Acm1 contains substrate-like degron sequences that have been conserved during evolution. A, sections of Acm1 containing conserved D box
(RXXL) and KEN box motifs from 6 Saccharomyces species aligned with ClustalW are shown. Consensus residues are highlighted in gray. Note that D box 2 is not
conserved. B, a similar alignment of Acm1 orthologs from more distantly related budding yeasts with S. cerevisiae Acm1, illustrating conservation of D box 1, D
box 3, and the KEN box. In both panels the asterisk indicates an invariant residue, “:” is a conservative substitution, and “.” is a semi-conservative substitution.
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complex (42). Under these condi-
tions the results were similar to
those observed with full-length
Cdh1 (Fig. 3D). The db3 and ken
mutations additively disrupted the
Acm1-WD40 interaction. Collec-
tively these results are consistent
with a model for APC inhibition
in which substrate-like degron se-
quences in Acm1 (in conjunction
with additional unidentified se-
quence) allow it to stably occupy the
substrate receptor site on the Cdh1
WD40 domain and competitively
inhibit association of true sub-
strates. This suggests that Acm1
acts as a pseudosubstrate inhibitor
of APCCdh1.
Interestingly, none of the muta-
tions we created in degron
sequences affected the cell cycle
expression profile of Acm1 in syn-
chronized cultures (Fig. 3E). All
Acm1mutants were absent fromG1
cells, appeared at the onset of S
phase, and disappeared rapidly in
mitosis, similar to wild-type Acm1.
The mutations also had no signifi-
cant impact on the stability of Acm1
in GAL promoter shutoff assays in
G1-arrested cells (Fig. 3F). Typi-
cally, mutation of D-box and KEN-
box sequences in APC substrates
results in significant stabilization in
vivo, particularly in G1. We previ-
ously provided evidence supporting
the existence of an APC-independ-
ent proteolytic mechanism for
Acm1 in late mitosis and G1 (49).
The lack of effects of degron muta-
tions onAcm1 stability is consistent
with these previous observations
and further supports pseudosub-
strate (rather than true substrate)
functions for the conserved central
D box 3 and KEN box.
D Box and KEN BoxMutations in
Acm1PreventAPCCdh1 Inhibition in
Vivo and in Vitro—If Acm1 inhibits
APCCdh1 activity by blocking associ-
ation of substrates with the Cdh1
WD40 domain, then the db3/ken
double mutation that compromises
binding to Cdh1 should also com-
promise APCCdh1 inhibition. We
tested this both in vivo and in vitro.
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FIGURE 3. Central D box and KEN box sequences in Acm1 are required for high affinity binding to the
Cdh1 WD40 domain. A, yeast strain YKA294 expressing endogenous 3FLAG-Cdh1 and containing centro-
meric plasmids expressing wild-type or the indicated mutant 3HA-Acm1 proteins from the ACM1 promoter
were grown to mid-log phase. An anti-FLAG IP was performed from cell extracts and co-purification of 3HA-
tagged protein monitored by anti-HA immunoblotting. Cdc28 is a loading control. B, the same procedure as in
panel A using strain YKA226 expressing endogenous 3HA-Acm1 and containing a centromeric plasmid
expressing 3FLAG-tagged N-terminal (amino acids 1–249) or C-terminal (amino acids 241–566) domains of
Cdh1 expressed from the ADH promoter. C, yeast strain YKA257 expressing endogenous 3HA-Hsl1 in an acm1
background was transformed with empty control plasmids (lane 1), a centromeric plasmid expressing 3FLAG-
Cdh1WD40 from the ADH promoter (lane 2), or the same 3FLAG-Cdh1WD40 plasmid plus a centromeric plas-
mid expressing 3HA-Acm1 from the GAL1 promoter. Cells were grown to mid-log phase in raffinose-containing
medium, then 2% galactose added and cells harvested after 2 h and subjected to -FLAG co-IP. D, the same
experiment described in panel A, except strain YKA247 contained centromeric plasmids expressing 3FLAG-
Cdh1WD40 (amino acids 241–566 only) from the ADH promoter and the indicated 3HA-Acm1 variant from the
ACM1 promoter. Also, NaCl concentration in the co-IP buffer was increased from 100 mM to 400 mM. G6PD is a
loading control. NC is a control lacking a 3HA-tagged Acm1 protein. E, synchronous cultures of strain YKA254
harboring centromeric plasmids expressing wild-type or the indicated mutant 3HA-Acm1 protein from the
ACM1 promoter were obtained by G1 -factor arrest and then released into fresh medium. Samples taken at the
indicated time points were analyzed by anti-HA, anti-Clb2, and anti-G6PD (loading control) immunoblotting,
and -factor was added back at 60 min to re-arrest cells in the subsequent G1. cyc, asynchronous cycling cells.
F, the stability of HA-Acm1 and the HA-Acm1-db1/db3/ken mutant were assessed by promoter shutoff in
-factor-arrested G1 YKA150 cells. After arrest, expression was induced with galactose for 2 h and quenched by
addition of glucose and cycloheximide (time 0). The level of each protein at the indicated time points was
monitored by anti-HA immunoblotting. G6PD is a loading control.
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growth arrest like wild-type Acm1 and the Acm1-db3 mutant
exhibited only a slight decrease in suppression (Fig. 4A), sug-
gesting little to no loss of APCCdh1 inhibition. In contrast, the
Acm1-db3/ken double mutant and the Acm1-db1/db3/ken tri-
ple mutant exhibited dramatically reduced suppression of the
Cdh1-induced arrest. The residual
suppression observed with these
two mutants may result from the
contribution of other regions in
Acm1 to Cdh1 binding revealed in
our co-IP studies with the WD40
domain. Based on this experiment,
though, the third D box and KEN
box are clearly critical for function
of Acm1 as an APCCdh1 inhibitor in
vivo, again consistent with a
pseudosubstrate mechanism.
We next compared the ability of
Acm1 and various degron mutants
to inhibit APCCdh1 activity in the
in vitro ubiquitination assay. At
an inhibitor concentration of 500
nM Acm1 almost completely inhib-
ited ubiquitination of Clb2 and
Hsl1667–872, whereas the Acm1-
db3/ken and Acm1-db1/db3/ken
mutants showed little to no inhibi-
tion (Fig. 4, B and C). We also eval-
uated inhibition across a range of
Acm1 concentrations and included
Acm1-db1 to test whether D box 1
contributes to APCCdh1 inhibition
in vitro (Fig. 4, E and F). Acm1 and
Acm1-db1 inhibited ubiquitination
of Clb2 andHsl1667–872 with similar
concentration dependence, con-
firming that D box 1 is not required
for Acm1 inhibitory function.
Acm1-db3/ken, in contrast, was a
relatively poor inhibitor, suggesting
that the decrease in binding toCdh1
compromised its ability to inhibit
APC activity. However, Acm1-db3/
ken appeared to retain a low level of
APCCdh1 inhibition, consistent with
the in vivo inhibition assay.
Acm1 Can Be Mono-ubiquiti-
nated by APCCdh1 in Vitro—Al-
thoughAcm1 is a potent inhibitor of
APCCdh1, whenwe tested it as a sub-
strate of APCCdh1 in vitro we found
it could be fairly efficiently ubiquiti-
nated (Fig. 5A, first two lanes). To
narrow down the region within
Acm1 responsible for the observed
ubiquitination we tested several
truncated forms of Acm1 lacking
sequence from the N and/or C ter-
mini. Acm1 fragments lacking the first 42 amino acids were
poor substrates, whereas fragments containing the intact N ter-
minus were all ubiquitinated to a similar extent (Fig. 5A).
Although the percentage of substrate converted to product
was substantial in these experiments, product formation
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FIGURE 4. The central D box and KEN box in Acm1 are required for full inhibition of APCCdh1 activity.
A, 10-fold serial dilutions of strain YKA247 expressing the indicated proteins from the GAL1 promoter on
centromeric plasmids were spotted on rich media plates containing either glucose or galactose and grown for
several days at 30 °C. The -HA immunoblot on the right compares the level of galactose-induced overexpres-
sion of each of the Acm1 variants. B, APC-catalyzed ubiquitination of Clb2 was assayed in the absence or
presence of 500 nM wild-type (wt) recombinant His6-Acm1 or the indicated Acm1 mutants. Relative activity was
obtained from the total ubiquitin conjugate signal (bracket). C, same as B except Hsl1667– 872 was used as the
substrate. D, the same quantities of the indicated recombinant His6-Acm1 proteins used in B and C were
compared by anti-His6 immunoblot to demonstrate equivalent concentrations. E, inhibition of APC-catalyzed
ubiquitination of Clb2 was measured as a function of inhibitor concentration for wild-type (wt) His6-Acm1 and
the db3/ken and db1 mutants. F, identical to E except Hsl1667– 872 was used as the substrate.
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appeared limited primarily to mono-ubiquitin conjugates
(based on the size of the distinct product bands). To confirm
this we compared product formation in the presence of
either ubiquitin or methyl-ubiquitin (which supports conju-
gation to substrate lysines but blocks poly-ubiquitin chain
formation) using Acm1, Clb2, or Hsl1667–872 as substrate.
Whereas the size of ubiquitin conjugates formed on Clb2 and
Hsl1667–872 was dramatically reduced by substitution of
methyl-ubiquitin as expected, the pattern of ubiquitin con-
jugation to Acm1 was unchanged (Fig. 5B). In our in vitro
assay, Acm1 can be efficiently
mono-ubiquitinated by APCCdh1
but is not a good substrate for
poly-ubiquitination.
To determine if the highly con-
served D box 1 was responsible for
the mono-ubiquitination observed
in Fig. 5A we compared APCCdh1-
catalyzed ubiquitin conjugation to
wild-type Acm1 and the Acm1-db1
mutant (Fig. 5C). The percentage of
substrate converted to mono-ubiq-
uitin conjugate was greatly reduced
in the absence of D box 1, demon-
strating that this sequence is a func-
tional APC degron in vitro even
though it is dispensable for
pseudosubstrate inhibition of APC.
D Box and KEN Box Mutations
Allow Acm1 to be Poly-ubiquiti-
nated by APCCdh1 in Vitro—Resid-
ual mono-ubiquitination was still
observed onAcm1-db1, which lacks
an intact D box 1. We expected this
residual ubiquitination to be
dependent on D box 3 and the KEN
box in the central region of Acm1
that are critical for high affinity
binding to the substrate receptor
site on Cdh1 and APCCdh1 inhibi-
tion. Surprisingly, the Acm1-db3/
ken mutant appeared to be poly-
ubiquitinated by APCCdh1 based on
increased size of ubiquitin conju-
gates and their sensitivity tomethyl-
ubiquitin, similar to Clb2 and
Hsl1667–872 (Fig. 5D). The poly-
ubiquitination of Acm1-db3/ken
was highly specific, because it
required the yeast E2 enzyme Ubc4,
yeast Cdh1, and yeast APC (Fig. 5E).
Moreover, it was largely independ-
ent of D box 1, because the triple
degron mutant Acm1-db1/db3/ken
supported similar poly-ubiquitina-
tion (Fig. 5E) and anAcm1 fragment
(residues 42–177) lacking the N ter-
minus and harboring the db3/ken
double mutation was an even more efficient substrate, being
completely converted to high molecular weight poly-ubiquitin
conjugates (Fig. 5F). These results are striking, because they
suggest the central D box and KEN box in Acm1, instead of
promoting ubiquitination like degrons in known APC sub-
strates, actually restrict Acm1 ubiquitination by APCCdh1.
The results also imply the existence of additional
sequence(s) within Acm1 capable of supporting its recogni-
tion by APCCdh1, consistent with the weak inhibitory func-
tion of Acm1-db3/ken in vivo (Fig. 4A) and the retention of
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FIGURE 5. The central D box and KEN box restrict poly-ubiquitination of Acm1 by APCCdh1. A, full-length
Acm1 (amino acids 1–209) and N- and C-terminal truncated forms were synthesized and 35S-labeled by in vitro
coupled transcription/translation and used as substrates in an APCCdh1 ubiquitination assay. B, products of
APCCdh1-catalyzed reactions using ubiquitin and methylated ubiquitin (me-Ubiquitin) were compared for the
35S-labeled substrates Acm1, Clb2, and Hsl1667– 872. Arrows indicate the unmodified substrates. C, ubiquitina-
tion of Acm1 and Acm1-db1 by APCCdh1 were compared. The dominant mono-ubiquitin product (mono-ub) is
indicated. The percentage of substrate converted to mono-ubiquitin conjugate was determined with Image-
QuaNT. D, products of APCCdh1-catalyzed reactions using ubiquitin and methyl-ubiquitin were compared for
the 35S-labeled substrates wild-type (wt) Acm1 and the Acm1-db3/ken mutant. E, ubiquitination of wild-type
Acm1, Acm1-db3/ken, and Acm1-db1/db3/ken by APCCdh1 were compared. For Acm1-db3/ken, the depend-
ence of poly-ubiquitination on yeast Ubc4 and Cdh1 are also shown. F, ubiquitination of full-length Acm1-(1–
209) and the wild-type and db3/ken forms of an Acm1 fragment encompassing residues 42–177 by APCCdh1
was compared. Arrows point to unmodified substrate. Note the complete conversion of the Acm142–177 db3/
ken substrate to poly-ubiquitin conjugates.
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some binding affinity for the Cdh1 WD40 domain observed
in the low salt co-IP experiments (not shown).
DISCUSSION
From this study we conclude that Acm1 is a general
pseudosubstrate inhibitor of APCCdh1 and that inhibition is
independent of regulatory CDK phosphorylation and 14-3-3
protein binding. Acm1 inhibits the ubiquitination of several
well characterizedAPCCdh1 substrates in vitro. Our results sug-
gest that inhibition of APC activity occurs via the stable binding
of Acm1 to the WD40 domain of Cdh1, which competitively
blocks substrate binding. The interaction between Acm1 and
theCdh1WD40domain and inhibition ofAPCactivity are both
dependent on a conserved D box and KEN box in the central
region of Acm1. Acm1 mutants lacking these degron
sequences, despite compromised APC inhibitory activity, are
poly-ubiquitinated like substrates by APCCdh1, demonstrating
that Acm1 contains the necessary structural elements for asso-
ciation with APC as a substrate (including acceptor lysines in
appropriate positions). Acm1 therefore joins Emi1 andMad3 as
a family of proteins that negatively regulate APC activity by a
pseudosubstrate mechanism.While our manuscript was under
review, two additional reports appeared describing similar roles
for Acm1 D and KEN boxes in pseudosubstrate inhibition of
APCCdh1 (50, 51).
Pseudosubstrate inhibition appears to be a commonly
evolvedmechanism for regulatingAPCactivity. A relatedmode
of APC inhibition was also found to be biologically relevant
recently. Substrates can inhibit the proteolysis of other sub-
strates through simple competition for APC binding. Most
notably, the Schizosaccharomyces pombe mes1 protein, previ-
ously identified as a meiotic inhibitor of APC (52), also turns
out to be a true APC substrate (53). Its presence duringmeiosis
may be sufficient to inhibit the complete destruction of cyclin B
simply by occupying APC binding sites long enough. It remains
to be seen if there is a post-translational regulatory switch that
converts mes1 from an inhibitor into a substrate. Also, mouse
securin has been shown to inhibit cyclin B proteolysis to regu-
late mitotic entry by a substrate competition mechanism (54).
These observations suggest that affinity of substrates for APC
may help dictate the timing of their ultimate destruction, in
addition to a previous proposal suggesting that processivity dic-
tates the order of substrate degradation byAPC (55). The resid-
ual inhibition of APCCdh1 by the Acm1-db3/ken mutant in our
studies may represent a form of substrate competition.
There is an important distinction between the pseudosub-
strate mechanisms of Emi1 and Acm1. Emi1 contains a C-ter-
minal zinc binding domain that is essential for APC inhibition
(39). A separate D box in Emi1 is required for recognition by
APC. Thus, binding and inhibition are provided by two distinct
regions of Emi1. Loss of the zinc binding domain converts Emi1
from an inhibitor into a D box-dependent substrate. Acm1, on
the other hand, does not contain a zinc binding domain. And in
contrast to Emi1, mutation of degron sequences themselves
converted Acm1 from an inhibitor into a substrate, at least in
vitro. This is a very surprising result, because in all cases
reported so far, mutations in degron sequences either have no
effect or reduce ubiquitination and proteolysis of substrates.
But in Acm1, mutation of the conserved central D and KEN
boxes resulted in greatly increased poly-ubiquitination.
The poly-ubiquitination of Acm1-db3/ken and the residual
APCCdh1 inhibition and WD40 domain binding exhibited by
Acm1-db3/ken reveal that other sequences in addition toDbox
3 and the KEN box must exist within Acm1 and contribute to
the interactionwith Cdh1. The highly conservedD box 1would
seem a likely candidate but mutation of this sequence had no
significant effect on the poly-ubiquitination of Acm1-db3/ken
even though it did contribute to the mono-ubiquitination of
wild-typeAcm1.Moreover, a truncated formof theAcm1-db3/
kenmutant lacking the N-terminal 42 amino acids that contain
D box 1 was an even more efficient substrate than the full-
length db3/ken mutant. This implicates sequences near the N
and/orC termini as contributors toAPC inhibition. So far these
sequences remain unidentified.
D box 1 is very strictly conserved in Acm1 orthologs, and it
was surprising that it had no effect on Cdh1 binding and
APCCdh1 inhibition. Interestingly, a recent report identified D
box 1 as a functional degron for targeting by APCCdc20 in early
anaphase (50). Our previous study found Acm1 proteolysis in
late anaphase and G1 to be independent of APC, however this
additional mode of regulation in early anaphase (which we pos-
sibly missed due to occlusion of the N-terminal D box 1 by an
epitope tag) provides an explanation for the strict conserva-
tion of D box 1 and suggests that the multiple degron motifs
in Acm1 allow it to be recognized as a substrate by one form
of the APC and act as a potent inhibitor of the other form.
Consistent with this, Enquist-Newman et al. (50) found that
Acm1 was unable to inhibit APCCdc20 activity. The presence
of distinct degrons within a single protein that are recog-
nized by both forms of the APC makes Acm1 a unique and
useful model for better understanding the determinants for
substrate recognition.
What makes the central degron motifs of Acm1 such effec-
tive inhibitors of APCCdh1? The answer is currently unclear, but
our results highlight the important role that sequence context
must play in modulating degron function. We speculate that
APC inhibition results from the unusually stable interaction
betweenAcm1 and the Cdh1WD40 domain (mediated both by
the central degron motifs and other sequences). Although evi-
dence suggests a clear role for co-activators in substrate degron
binding (19, 20) these interactions are difficult to detect in
many cases, suggesting that they tend to be transient, or
weak. In contrast, Acm1 forms a stoichiometric, highly sta-
ble complex with Cdh1 (42) that can prevent substrate bind-
ing, suggesting that the affinity of this interaction is much
higher than Cdh1-substrate interactions. It has been pro-
posed that the WD40 domain of Cdh1 directly contacts sub-
strate D boxes (20). Our results are fully consistent with this
model and suggest that stable interaction between substrate
degrons and the co-activator proteins may be selected
against, being mutually exclusive with processive ubiquitin
ligation. In the case of Acm1, the high affinity interaction
with Cdh1 appears to serve two purposes. It blocks recogni-
tion of APCCdh1 substrates while simultaneously protecting
itself from APCCdh1-mediated proteolysis, resulting in
highly stable and potent APCCdh1 inhibition.
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Why would weak interactions between substrates and co-
activators be preferred? One possibility is that processive
assembly of a poly-ubiquitin chain on substrates requires dis-
engagement of substrate from the co-activator after one ubiq-
uitin ligation event to allow repositioning in the ligase active
site prior to the next one. It is important to note here that
degron binding sites on the core APC are thought to exist as
well, and it has been proposed that cooperativity between
degron recognition sites on the co-activators and core APC
might be one mechanism contributing to functional substrate
binding (18, 21, 24, 25). Recently, a novel motif called the TEK
box present in both ubiquitin and several human APC sub-
strates was identified that plays an important role in substrate
binding and poly-ubiquitination (56). The authors proposed
that a TEK box binding site on APC or the E2 UbcH10 first
orients substrates in the active site for initial ubiquitin transfer
and subsequently the TEK box of the conjugated ubiquitin dis-
places the substrate TEK box to allow poly-ubiquitin chain for-
mation (56). Although there is no evidence yet for a TEK box-
like mechanism in yeast, this model supports the idea that
substrates are repositioned in the APC active site after the ini-
tial ubiquitin transfer to facilitate assembly of the large, bulky
poly-ubiquitin chain. A highly stable substrate-co-activator
interaction may not allow disengagement, and the processive
ubiquitin transfer reaction would be blocked. This is consistent
with our observation that wild-type Acm1 can be mono-ubiq-
uitinated fairly efficiently in vitro but that poly-ubiquitin chain
assembly does not occur unless affinity of the Cdh1-Acm1
interaction is greatly reduced bymutation of the central degron
sequences. However, other mechanisms are possible as well.
Testing thismodel and other possiblemodels is clearly an inter-
esting and important focus of future studies aimed at under-
standing substrate recognition and APC activation by the
Cdc20 and Cdh1 co-activator proteins.
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